Inge Thomsen Bernstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9141931/publications.pdf

Version: 2024-02-01

85 papers

6,481 citations

147566 31 h-index 78 g-index

92 all docs 92 docs citations

times ranked

92

6378 citing authors

#	Article	IF	CITATIONS
1	Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut, 2013, 62, 812-823.	6.1	630
2	Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut, 2008, 57, 704-713.	6.1	591
3	The risk of extraâ€colonic, extraâ€endometrial cancer in the Lynch syndrome. International Journal of Cancer, 2008, 123, 444-449.	2.3	481
4	Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). Journal of Medical Genetics, 2007, 44, 353-362.	1.5	461
5	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut, 2017, 66, 464-472.	6.1	411
6	Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nature Genetics, 2014, 46, 107-115.	9.4	410
7	Cancer risk and survival in <i>path_MMR</i> carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut, 2018, 67, 1306-1316.	6.1	410
8	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genetics in Medicine, 2020, 22, 15-25.	1.1	365
9	The Clinical Features of Ovarian Cancer in Hereditary Nonpolyposis Colorectal Cancer. Gynecologic Oncology, 2001, 82, 223-228.	0.6	219
10	Lynch Syndrome Caused by Germline <i>PMS2</i> Mutations: Delineating the Cancer Risk. Journal of Clinical Oncology, 2015, 33, 319-325.	0.8	177
11	Cancer Risks for <i>PMS2</i> -Associated Lynch Syndrome. Journal of Clinical Oncology, 2018, 36, 2961-2968.	0.8	147
12	Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut, 2017, 66, 1657-1664.	6.1	127
13	The pelvic floor muscles: Muscle thickness in healthy and urinary-incontinent women measured by perineal ultrasonography with reference to the effect of pelvic floor training. Estrogen receptor studies., 1997, 16, 237-275.		112
14	Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecologic Oncology, 2011, 121, 462-465.	0.6	110
15	Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Familial Cancer, 2010, 9, 109-115.	0.9	103
16	Hereditary Non-Polyposis Colorectal Cancer: Clinical Features and Survival Results from the Danish HNPCC Register. Scandinavian Journal of Gastroenterology, 1997, 32, 572-576.	0.6	84
17	Reduced Frequency of Extracolonic Cancers in Hereditary Nonpolyposis Colorectal Cancer Families with Monoallelic hMLH1Expression. American Journal of Human Genetics, 1997, 61, 129-138.	2.6	79
18	Relationship between method of anastomosis and anastomotic failure after right hemicolectomy and ileoâ€caecal resection: an international snapshot audit. Colorectal Disease, 2017, 19, e296.	0.7	75

#	Article	IF	Citations
19	Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Familial Cancer, 2008, 7, 303-307.	0.9	66
20	Sarcomas associated with hereditary nonpolyposis colorectal cancer: broad anatomical and morphological spectrum. Familial Cancer, 2009, 8, 209-213.	0.9	58
21	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncology, The, 2021, 22, 1014-1022.	5.1	58
22	Interobserver variability in the evaluation of mismatch repair protein immunostaining. Human Pathology, 2010, 41, 1387-1396.	1.1	55
23	Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report. Hereditary Cancer in Clinical Practice, 2017, 15, 18.	0.6	49
24	Computational and cellular studies reveal structural destabilization and degradation of MLH1 variants in Lynch syndrome. ELife, 2019, 8 , .	2.8	49
25	Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers. Genetics in Medicine, 2020, 22, 1524-1532.	1.1	44
26	Hereditary non-polyposis colorectal cancer (HNPCC): phenotype-genotype correlation between patients with and without identified mutation. Human Mutation, 2002, 20, 20-27.	1.1	43
27	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 8.	0.6	42
28	Role for Genetic Anticipation in Lynch Syndrome. Journal of Clinical Oncology, 2009, 27, 360-364.	0.8	41
29	Mismatch repair defective breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Research and Treatment, 2010, 120, 777-782.	1.1	39
30	An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome. Clinical and Experimental Gastroenterology, 2021, Volume 14, 181-197.	1.0	36
31	Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population. Familial Cancer, 2009, 8, 75-83.	0.9	35
32	Challenges in the Identification of MSH6-Associated Colorectal Cancer. American Journal of Surgical Pathology, 2011, 35, 1391-1399.	2.1	34
33	Intra- and inter- observer variations in classification of urinary flow curve patterns. Neurourology and Urodynamics, 1990, 9, 535-539.	0.8	30
34	A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointestinal Endoscopy, 2016, 84, 115-125.e4.	0.5	30
35	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genetics in Medicine, 2021, 23, 705-712.	1.1	28
36	Distinct Gene Expression Signatures in Lynch Syndrome and Familial Colorectal Cancer Type X. PLoS ONE, 2013, 8, e71755.	1.1	28

#	Article	IF	CITATIONS
37	Survival by colon cancer stage and screening interval in Lynch syndrome: a prospective Lynch syndrome database report. Hereditary Cancer in Clinical Practice, 2019, 17, 28.	0.6	27
38	Risk of gynecologic cancers in Danish hereditary non-polyposis colorectal cancer families. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 1129-1135.	1.3	25
39	Hereditary colorectal cancer diagnostics: morphological features of familial colorectal cancer type X versus Lynch syndrome. Journal of Clinical Pathology, 2012, 65, 352-356.	1.0	25
40	Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. International Journal of Technology Assessment in Health Care, 2007, 23, 89-95.	0.2	24
41	Risk of post-colonoscopy colorectal cancer in Denmark: time trends and comparison with Sweden and the English National Health Service. Endoscopy, 2019, 51, 733-741.	1.0	24
42	Gain of chromosomal region 20q and loss of 18 discriminates between Lynch syndrome and familial colorectal cancer. European Journal of Cancer, 2013, 49, 1226-1235.	1.3	23
43	A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer. International Journal of Cancer, 2014, 134, 939-947.	2.3	22
44	Hepatoblastoma in two cousins in a family with adenomatous polyposis. Diseases of the Colon and Rectum, 1992, 35, 373-374.	0.7	21
45	Functional characterization of <i>MLH1</i> missense variants identified in lynch syndrome patients. Human Mutation, 2012, 33, 1647-1655.	1.1	21
46	Barrett's Esophagus and Esophageal Adenocarcinoma Endoscopic and Histologic Surveillance. Scandinavian Journal of Gastroenterology, 1993, 28, 193-196.	0.6	19
47	MSH6 Mutations are Frequent in Hereditary Nonpolyposis Colorectal Cancer Families With Normal pMSH6 Expression as Detected by Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 470-477.	0.6	18
48	Functional examination of MLH1, MSH2, and MSH6 intronic mutations identified in Danish colorectal cancer patients. BMC Medical Genetics, 2013, 14, 103.	2.1	18
49	Outcome of 24â€years national surveillance in different hereditary colorectal cancer subgroups leading to more individualised surveillance. Journal of Medical Genetics, 2017, 54, 297-304.	1.5	18
50	Surveillance for urinary tract cancer in Lynch syndrome. Familial Cancer, 2013, 12, 279-284.	0.9	17
51	The results of gynecologic surveillance in families with hereditary nonpolyposis colorectal cancer. Gynecologic Oncology, 2014, 133, 526-530.	0.6	17
52	Risk of Synchronous and Metachronous Colorectal Cancer: Population-Based Estimates in Denmark with Focus on Non-Hereditary Cases Diagnosed After Age 50. Scandinavian Journal of Surgery, 2019, 108, 152-158.	1.3	17
53	latrogenic Psoas Abscess. Scandinavian Journal of Urology and Nephrology, 1991, 25, 85-86.	1.4	16
54	A Parametric Model for Analyzing Anticipation in Genetically Predisposed Families. Statistical Applications in Genetics and Molecular Biology, 2009, 8, 1-11.	0.2	16

#	Article	IF	Citations
55	Awareness of Endometrial Cancer Risk and Compliance With Screening in Hereditary Nonpolyposis Colorectal Cancer. Obstetrics and Gynecology, 2012, 120, 1005-1012.	1.2	16
56	Vaginal ultrasonography: a diagnostic tool for urethral diverticulum. Acta Obstetricia Et Gynecologica Scandinavica, 1996, 75, 188-190.	1.3	15
57	Sessile serrated polyps of the colorectum are rare in patients with Lynch syndrome and in familial colorectal cancer families. Familial Cancer, 2008, 7, 157-162.	0.9	15
58	The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers. Genetics in Medicine, 2016, 18, 405-409.	1.1	15
59	Follow-up after rectal cancer: developing and testing a novel patient-led follow-up program. Study protocol. Acta Oncol \tilde{A}^3 gica, 2017, 56, 307-313.	0.8	14
60	Biopsies of colorectal clinical polyps – emergence of diagnostic information on deeper levels. Pathology Research and Practice, 2009, 205, 231-240.	1.0	11
61	Validation of a Selfâ€Concept Scale for Lynch Syndrome in Different Nationalities. Journal of Genetic Counseling, 2011, 20, 308-313.	0.9	11
62	Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. European Journal of Cancer, 2021, 148, 124-133.	1.3	11
63	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. Journal of Clinical Medicine, 2021, 10, 2856.	1.0	11
64	Bricker's Ileal Conduit Urinary Diversion with a Simple Non-Refluxing Uretero Ileal Anastomosis. Scandinavian Journal of Urology and Nephrology, 1991, 25, 29-33.	1.4	10
65	Colonoscopy adverse events: are we getting the full picture?. Scandinavian Journal of Gastroenterology, 2020, 55, 979-987.	0.6	10
66	Biomedical informatics as support to individual healthcare in hereditary colon cancer: the Danish HNPCC system. Human Mutation, 2011, 32, 551-556.	1.1	9
67	Survival of patients with <scp>S</scp> tage <scp>III</scp> colon cancer is improved in hereditary nonâ€polyposis colorectal cancer compared with sporadic cases. A <scp>D</scp> anish registry based study. Colorectal Disease, 2013, 15, 816-823.	0.7	9
68	Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum. International Journal of Cancer, 2021, 148, 512-513.	2.3	9
69	Functional characterization of rare missense mutations in MLH1 and MSH2 identified in Danish colorectal cancer patients. Familial Cancer, 2009, 8, 489-500.	0.9	8
70	Limited impact on self-concept in individuals with Lynch syndrome; results from a national cohort study. Familial Cancer, 2011, 10, 633-639.	0.9	7
71	Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation. Familial Cancer, 2012, 11, 579-585.	0.9	7
72	Presymptomatic diagnosis using a deletion of a single codon in families with hereditary non-polyposis colorectal cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 570, 89-96.	0.4	6

#	Article	IF	Citations
73	The Apparent Genetic Anticipation in PMS2-Associated Lynch Syndrome Families Is Explained by Birth-cohort Effect. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1010-1014.	1.1	6
74	Bladder function in patients with myotonic dystrophy. Neurourology and Urodynamics, 1992, 11, 219-223.	0.8	5
75	Barrett's Oesophagus. Digestive Diseases, 1994, 12, 98-105.	0.8	5
76	Balancing Life with an Increased Risk of Cancer: Lived Experiences in Healthy Individuals with Lynch Syndrome. Journal of Genetic Counseling, 2014, 23, 778-784.	0.9	5
77	An effect from anticipation also in hereditary nonpolyposis colorectal cancer families without identified mutations. Cancer Epidemiology, 2009, 33, 231-234.	0.8	4
78	Deranged Wnt signaling is frequent in hereditary nonpolyposis colorectal cancer. Familial Cancer, 2011, 10, 239-243.	0.9	4
79	Risk of multiple colorectal cancer development depends on age and subgroup in individuals with hereditary predisposition. Familial Cancer, 2019, 18, 183-191.	0.9	4
80	Malignant Mesenchymoma of the Scrotum. Scandinavian Journal of Urology and Nephrology, 1991, 25, 315-317.	1.4	3
81	Implementing population-based screening for Lynch syndrome Journal of Clinical Oncology, 2013, 31, 6600-6600.	0.8	3
82	Differential expression of CK20, \hat{l}^2 -catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X. BMC Clinical Pathology, 2017, 17, 11.	1.8	2
83	HNPCC-associated synchronous early-stage signet-ring cell carcinomas of colonic origin. A comparative morphological and immunohistochemical study of an intramucosal and a submucosal example. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009. 454. 115-124.	1.4	1
84	Registries. , 2010, , 595-612.		0
85	Abstract LB-439: Distinct tumorigenic pathways within the hereditary nonpolyposis colorectal cancer. , 2012, , .		O